# A Study to Assess the Safety and Efficacy of Prograf and MR4 in Kidney Transplantation Patients

> **NCT00720265** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 135 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Prograf
- **DRUG:** MR4

## Key facts

- **NCT ID:** NCT00720265
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2008-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00720265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00720265, "A Study to Assess the Safety and Efficacy of Prograf and MR4 in Kidney Transplantation Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00720265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*